- Home
- AENT vs ANNX Comparison
AENT vs ANNX Comparison
Compare AENT & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- ANNX
- Stock Information
- Founded
- AENT 1990
- ANNX 2011
- Country
- AENT United States
- ANNX United States
- Employees
- AENT N/A
- ANNX N/A
- Industry
- AENT Durable Goods
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- AENT Consumer Discretionary
- ANNX Health Care
- Exchange
- AENT Nasdaq
- ANNX Nasdaq
- Market Cap
- AENT 254.3M
- ANNX 253.8M
- IPO Year
- AENT N/A
- ANNX 2020
- Fundamental
- Price
- AENT $6.80
- ANNX $2.52
- Analyst Decision
- AENT Strong Buy
- ANNX Strong Buy
- Analyst Count
- AENT 1
- ANNX 5
- Target Price
- AENT $10.00
- ANNX $13.00
- AVG Volume (30 Days)
- AENT 85.7K
- ANNX 1.6M
- Earning Date
- AENT 09-10-2025
- ANNX 11-13-2025
- Dividend Yield
- AENT N/A
- ANNX N/A
- EPS Growth
- AENT 228.78
- ANNX N/A
- EPS
- AENT 0.30
- ANNX N/A
- Revenue
- AENT $1,063,457,000.00
- ANNX N/A
- Revenue This Year
- AENT $4.85
- ANNX N/A
- Revenue Next Year
- AENT N/A
- ANNX N/A
- P/E Ratio
- AENT $23.83
- ANNX N/A
- Revenue Growth
- AENT N/A
- ANNX N/A
- 52 Week Low
- AENT $1.68
- ANNX $1.29
- 52 Week High
- AENT $11.57
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- AENT 59.67
- ANNX 57.40
- Support Level
- AENT $5.03
- ANNX $2.32
- Resistance Level
- AENT $7.54
- ANNX $2.70
- Average True Range (ATR)
- AENT 0.70
- ANNX 0.16
- MACD
- AENT 0.11
- ANNX 0.06
- Stochastic Oscillator
- AENT 70.75
- ANNX 72.06
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.